Friday, November 13, 2026

EUR/CHF Bearish Momentum With A 1% Drop In The Last 21 Sessions

EUR/CHF Bearish Momentum With A 1% Drop In The Last 21 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.7% for the last 21 sessions. At 16:07 EST on Sunday, 23 July, EUR/CHF (EURCHF) is $0.96.

EUR/CHF's yearly highs and lows, it's 2.195% up from its 52-week low and 4.566% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a positive 0.02%, a negative 0.09%, and a positive 0.22%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.27% (last week), 0.19% (last month), and 0.22% (last quarter), respectively.

News about

  • Usd/jpy trades with modest intraday losses below 140.00, lacks follow-through. According to FXStreet on Friday, 21 July, "A generally weaker tone around the equity markets, along with concerns over slowing growth in China, the worsening US-China relations and geopolitical risks, benefit the safe-haven Japanese Yen (JPY), which, in turn, exert pressure on the USD/JPY pair. ", "The USD/JPY pair edges lower during the Asian session on Friday and moves away from over a one-week high, around the 140.50 region touched the previous day. "
  • Usd/jpy prints four-day winning streak above 140.00 despite upbeat Japan inflation, sluggish yields. According to FXStreet on Friday, 21 July, "Looking ahead, a light calendar may restrict immediate USD/JPY moves before the next week's monetary policy meetings of the Fed and the BoJ. ", "Although the 200-DMA puts a floor under the USD/JPY prices near 136.90, the Yen pair's immediate upside appears guarded by the 50-DMA hurdle of 140.60."
  • Usd/jpy rallies to near 142.00 as US dollar jumps and boj policy seems unchanged. According to FXStreet on Friday, 21 July, "The USD/JPY pair is swiftly marching towards the critical resistance of 142.00 in the European session. ", "The rally in USD/JPY is backed by expectations that policy divergence between the Fed and the Bank of Japan (BoJ) would escalate further as the Fed is expected to raise interest rates further while the BoJ will continue maintaining its decade-long ultra-dovish policy stance. "
  • Usd/jpy forecast: shows resilience against Japanese yen - 21 July 2023. According to DailyForex on Friday, 21 July, "If the USD/JPY pair manages to break above the ¥140.50 level, it could pave the way for further gains towards the ¥142.50 level, which has held historical importance.", "Traders are advised to remain cautious and prepare for potential volatility in the USD/JPY pair. "
  • Usd/jpy soars past 141.00 as boj’s would sticks to dovish stance, weakening the JPY. According to FXStreet on Friday, 21 July, "USD/JPY rallied back above the 141.00 figure after rumors the Bank of Japan (BoJ) would not change its Yield Curve Control (YCC) emerged, spurring an upward reaction in the USD/JPY due to Japanese Yen (JPY) softness. ", "The USD/JPY seesawed around 140.00 throughout most of the Asian session before the Reuters report surfaced."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com